

## Thomas Glanzmann to retire as Grifols Chairman and will be succeeded by Board member Anne-Catherine Berner

**Barcelona, Spain, Feb. 25, 2025** – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma derived medicines, today announced that its Chairman of the Board of Directors, Thomas Glanzmann, has decided not to stand for reelection at the 2025 annual general meeting (AGM) after concluding his two-year agreement to act as Executive Chairman. He will be succeeded as non-executive Chair by Grifols independent Board member Anne-Catherine Berner.

Glanzmann, who has also decided to retire from the Board after being a member for nearly 20 years, became a director in 2006, the year the company listed on the Spanish Stock Exchange. He was named Executive Chairman in February 2023 and also assumed the CEO role three months later. In April 2024, he transitioned the CEO position to Nacho Abia and became non-Executive Chairman in September.

During his long tenure, first as a Grifols Board member and Vice Chairman and then later with executive responsibilities, Glanzmann was a significant contributor to guiding Grifols through periods of growth and transformation as the company expanded internationally to become a global leader in plasma and transfusion medicine.

His steady leadership left a permanent and positive mark on the organization. From the Board, he contributed to the establishment of the company’s first Strategy Office. More recently, as Executive Chairman and CEO, he worked alongside the management team to lead the company out of the pandemic and into a year of record revenue in 2023, while taking decisive steps to lower its debt.

Glanzmann, together with the Grifols family, was critical in recruiting Abia as CEO and setting up a new leadership team that, with the support of the Board and the family, introduced significant governance changes in the company. In 2024, he enabled Grifols to work through an unprecedented short-seller attack as well as Brookfield’s potential interest in acquiring the company as it went on to deliver excellent financial results through the first nine months of the year.

“It has been an honor and privilege to Chair the Board and be CEO of this great 115-year-old company, especially during the latest challenging and transformative times,” said Glanzmann. “I am proud of the progress we have made during my stewardship, which would not have been possible without the great support of my colleagues on the Board, the Grifols family, the relentless dedication of the management team and, of course, the incredible commitment of Grifols employees to our mission of saving and improving lives. We laid the foundation for a greater future, which I know will be taken to the next level by Nacho and my Chair successor,

Anne-Catherine Berner, who brings significant governance experience and a new perspective that will greatly benefit the company as it moves forward.”

Anne-Catherine Berner, an independent Board member since 2024, currently chairs the Grifols Appointment and Remuneration Committee. She currently serves on Boards in Sweden, Germany and Switzerland and is the Chairwoman of the Board, Foundation for Children’s Trauma Hospital and Institution Nadija in Helsinki. She was a Minister of Transport in Finland for four years and was also the Chairwoman and CEO of Vallila Interior AB Oy, a family-owned company in Finland.

“It is a great honor for me to be nominated to chair Grifols, an exceptional company revered for its long-time commitment to providing patients with trusted plasma medicines and other healthcare solutions,” said Anne-Catherine Berner. “I look forward to collaborating closely with Thomas over the next few months as part of the transition, and then with the rest of the Board on an ongoing basis to ensure Grifols continues on its strategic growth path and realizes its full potential for all stakeholders.”

“All of us at Grifols are very grateful that Thomas has been part of the team for almost 20 years. His advice, business vision, ethics and commitment to the safety of our products have been instrumental in building the company we have today,” said Raimon Grifols, Grifols Vice-Chairman. “His stewardship and unequalled commitment, especially during recent challenging times, have been critical in contributing to, protecting and defending the reputation we have built over our 115-year history. Thank you for everything, Thomas.”

With the appointment of an independent chairperson, the position of independent lead director will no longer be applicable. Glanzmann will remain Chairman until the 2025 AGM, after which time the company has no plans to replace the Board vacancy and the total number of Board members will be reduced to 12.

## **MEDIA CONTACTS**

### **Grifols Press Office**

[media@grifols.com](mailto:media@grifols.com)

Tel. +34 93 571 00 02

Spain

Duomo Comunicación

Tel.: +34 91 311 92 89 – +34 91 311 92 90

Raquel Lumbreras (Tel. +34 659 572 185)

[Raquel\\_lumbreras@duomocomunicacion.com](mailto:Raquel_lumbreras@duomocomunicacion.com)

Borja Gómez (Tel. + 34 659 572 185)

[Borja\\_gomez@duomocomunicacion.com](mailto:Borja_gomez@duomocomunicacion.com)

## **INVESTORS**

### **Investors Relations & Sustainability**

[inversores@grifols.com](mailto:inversores@grifols.com) - [investors@grifols.com](mailto:investors@grifols.com)

[sostenibilidad@grifols.com](mailto:sostenibilidad@grifols.com) - [sustainability@grifols.com](mailto:sustainability@grifols.com)

Tel. +34 93 571 02 21

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit [grifols.com](http://grifols.com)

## **LEGAL DISCLAIMER**

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.